Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aptinyx Inc (NQ: APTX )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, May 18, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aptinyx Inc

< Previous 1 2 3 4 5 6 Next >
The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings
Biotech stocks rebounded along with the broader market in the week ending March 18, as risk appetite returned. Multiple conference presentations, clinical readouts and earnings news dictated sentiment... 
Via Benzinga
28 Stocks Moving in Wednesday's Pre-Market Session
Gainers Guardion Health Sciences, Inc. (NASDAQ: GHSI) rose 46.4% to $0.4098 in pre-market trading after jumping around 48% on Tuesday. Guardion Health Sciences recently reported... 
Via Benzinga
Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Fibromyalgia
From Aptinyx Inc.
Via Business Wire
Aptinyx Hosts Virtual Portfolio Review Event to Showcase NYX-2925 in Chronic Pain and Provide Update on Clinical Development Programs
From Aptinyx Inc.
Via Business Wire
Aptinyx to Present at the SVB Leerink 11th Annual Global Healthcare Conference
From Aptinyx Inc.
Via Business Wire
Aptinyx Announces Formation of Scientific Advisory Board
From Aptinyx Inc.
Via Business Wire
Aptinyx Highlights Key Goals and Anticipated Development Milestones for 2022
From Aptinyx Inc.
Via Business Wire
Aptinyx to Host Virtual Portfolio Review Event on February 9th, 2022
From Aptinyx Inc.
Via Business Wire
Aptinyx Initiates Phase 2b Study of NYX-783 in Patients with Post-Traumatic Stress Disorder
From Aptinyx Inc.
Via Business Wire
Aptinyx to Present at the 40th Annual J.P. Morgan Healthcare Conference
From Aptinyx Inc.
Via Business Wire
Mid-Afternoon Market Update: Nasdaq Falls Over 1%; Reata Pharmaceuticals Shares Plummet
Toward the end of trading Thursday, the Dow traded up 0.17% to 35,814.21 while the NASDAQ fell 1.13% to 15,608.30. The S&P also fell, dropping 0.28% to 4,688.20. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
The Daily Biotech Pulse: Reata Plunges On Adcom Snub, AstraZeneca Antibody Cocktail Authorized For COVID-19 Prevention, NeuroSense IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Committee Votes Against Recommending Approval Of Kidney Disease Drug... 
Via Benzinga
Exposures COVID-19 Product Safety
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Aptinyx (NASDAQ:APTX) shares rose... 
Via Benzinga
The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setbacks For Merck's HIV Program, Decision Day For Daré
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Acadia Announces Positive Phase 3 Data For Trofinetide In Rett Syndrome... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers ACADIA Pharmaceuticals (NASDAQ:ACAD 
Via Benzinga
Aptinyx to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference
From Aptinyx Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Kezar Life Sciences (NASDAQ:KZR) stock rose 48.27% to $12.47 during Tuesday's pre-market session. The market value of their outstanding shares is at $612.8... 
Via Benzinga
Aptinyx Inc. (APTX) Q3 2021 Earnings Call Transcript
APTX earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Aptinyx Reports Third Quarter 2021 Financial Results and Recent Highlights
From Aptinyx Inc.
Via Business Wire
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces... 
Via Benzinga
Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy
From Aptinyx Inc.
Via Business Wire
Aptinyx to Report Third Quarter 2021 Financial Results on Tuesday, November 9, 2021
From Aptinyx Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Nutriband (NASDAQ:NTRB) shares rose 15.52% to $6.72 during Friday's pre-market session. The market value of their outstanding shares is at $49.8 million. T2... 
Via Benzinga
Aptinyx Appoints Gilmore O’Neill, M.B., M.M.Sc., to Board of Directors
From Aptinyx Inc.
Via Business Wire
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc... 
Via Benzinga
Aptinyx to Participate in 2021 Cantor Virtual Global Healthcare Conference
From Aptinyx Inc.
Via Business Wire
Aptinyx Secures $50 Million Growth Capital Credit Facility from K2 HealthVentures
From Aptinyx Inc.
Via Business Wire
Aptinyx to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
From Aptinyx Inc.
Via Business Wire
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19) Alkermes plc (NASDAQ: ALKS... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.